Edition:
United Kingdom

Shire PLC (SHP.L)

SHP.L on London Stock Exchange

3,461.00GBp
19 Jan 2018
Change (% chg)

8.50 (+0.25%)
Prev Close
3,452.50
Open
3,489.50
Day's High
3,529.00
Day's Low
3,458.00
Volume
3,825,018
Avg. Vol
2,930,030
52-wk High
5,067.00
52-wk Low
3,403.50

Chart for

About

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company's segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas... (more)

Overall

Beta: 1.54
Market Cap(Mil.): £35,231.62
Shares Outstanding(Mil.): 908.51
Dividend: 3.85
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.10 16.58
EPS (TTM): -- -- --
ROI: -- 14.84 10.60
ROE: -- 16.32 14.19

BRIEF-Shire Says ‍Thomas Dittrich Will Assume Role As CFO

* ‍THOMAS DITTRICH WILL ASSUME HIS ROLE AS CHIEF FINANCIAL OFFICER​

19 Jan 2018

BRIEF-Shire Says Granted EU marketing Authorization For ADYNOVI For Adults And Adolescents With Hemophilia A

* SHIRE GRANTED EU MARKETING AUTHORIZATION FOR ADYNOVI [ANTIHEMOPHILIC FACTOR (RECOMBINANT), PEGYLATED] FOR ADULTS AND ADOLESCENTS WITH HEMOPHILIA A​

15 Jan 2018

Shire cuts 2020 revenue target, prepares for spin-off of ADHD drugs

LONDON Shire ditched its revenue target of $20 billion by 2020 on Monday due to increased generic competition and new drugs from rivals, saying it would split its rare disease and hyperactivity medicines businesses to boost performance.

08 Jan 2018

Shire cuts 2020 revenue target, prepares for spin-off of ADHD drugs

LONDON Shire ditched its revenue target of $20 billion (14.8 billion pounds) by 2020 on Monday due to increased generic competition and new drugs from rivals, saying it would split its rare disease and hyperactivity medicines businesses to boost performance.

08 Jan 2018

UPDATE 2-Shire cuts 2020 revenue target, prepares for spin-off of ADHD drugs

* Shares fall 6 percent (Adds CEO comments, analyst reaction, closing share price)

08 Jan 2018

Shire to separate ADHD drugs ahead of possible spin-off, cuts outlook

LONDON, Jan 8 London-listed pharmaceutical group Shire said on Monday it would create two distinct business units for its rare disease and hyperactivity medicines ahead of deciding later this year whether to spin off the latter into a separately listed group.

08 Jan 2018

BRIEF-Shire Says Xiidra Approved By Health Canada To Treat Signs And Symptoms Of Dry Eye Disease

* XIIDRA APPROVED BY HEALTH CANADA TO TREAT SIGNS AND SYMPTOMS OF DRY EYE DISEASE

03 Jan 2018

BRIEF-Shire Files For FDA Approval Of New Plasma Manufacturing Facility In Covington, Georgia

* SHIRE FILES FOR FDA APPROVAL OF A NEW PLASMA MANUFACTURING FACILITY IN COVINGTON, GEORGIA TO SUPPORT GROWING IMMUNOLOGY FRANCHISE

27 Dec 2017

Shire's Hunter syndrome drug fails late-stage study

Shire Plc's experimental treatment for children with Hunter syndrome and cognitive impairment failed to meet the main and secondary goals of a late-stage clinical trial.

19 Dec 2017

UPDATE 1-Shire's Hunter syndrome drug fails late-stage study

Dec 19 Shire Plc's experimental treatment for children with Hunter syndrome and cognitive impairment failed to meet the main and secondary goals of a late-stage clinical trial.

19 Dec 2017

Earnings vs. Estimates